Joined: 03 Oct 2005
|Posted: Mon Nov 14, 2005 10:48 am Post subject: Inion and Cambridge to Produce Bioactive Medical Materials
|Inion and University of Cambridge Sign 3-Year Development Agreement to Produce New, Bioactive Medical Materials
Inion, a rapidly growing company focused on the development of novel biodegradable medical implants, has entered into a three-year collaboration agreement with The Cambridge Centre for Medical Materials at the University of Cambridge Department of Materials Science & Metallurgy.
The collaboration will focus on developing a new medical materials platform combining the proprietary Inion Optima[TM] biodegradable polymers with nano-phase bioactive ceramics under development at the University.
These new Biodegradable Bioactive Nano Composite (BBNC) materials are complementary to Inion’s own Optima PLUS[TM] bioactive platform in development, which combines Inion Optima[TM] polymers with N-methyl-pyrollidone (NMP). In time it is expected that both platforms will be used to manufacture innovative medical fixation devices for a broad range of clinical applications.
The Cambridge Centre for Medical Materials (CCMM) is world-renowned in the field of innovative medical materials. The centre was set up in 2000 by Prof. William Bonfield, at the University of Cambridge, Department of Materials Science and Metallurgy, and has strong links with the prestigious Orthopaedic Research Unit, headed by Prof. Neil Rushton, Professor of Orthopaedics at Addenbrooke’s Hospital.
The co-directors of CCMM, Dr Serena Best and Dr Ruth Cameron, and their research team are among the most highly regarded in the field of therapeutic materials, and the group’s research has pioneered the development of bioactive technologies to promote tissue healing.
Commenting on the agreement, Dr Cameron and Dr Best stated; “We are delighted to be entering into this project with Inion. The technologies that each partner has developed have the potential to converge and produce an entirely novel technology platform. Once this platform is established it will offer many potential applications throughout the body. Our experiences have shown that by carefully selecting complementary technologies we are able to deliver results that match, and even improve on, the body’s ability to heal itself.”
Auvo Kaikkonen, CEO of Inion said; “We are thrilled to be working with such a prestigious group as the CCMM. Through our many relationships with academic institutions across the world we have been able to develop technologies that offer real benefits to patients and clinicians alike. This latest project has the potential to match these achievements and provides greater breadth in our ability to develop next-generation biomaterials and medical implants designed to enhance the healing process.”
Inion will make a small financial contribution to the collaboration and has taken a non-exclusive, non-royalty bearing licence for commercialising any resulting products. The Company has an option to make the licence exclusive in return for making royalty payments on future product sales. The University of Cambridge will retain intellectual property rights to the use of the technology it is contributing to this collaboration.
This story was posted on 11 November 2005.